Skip to content

Released Nov 10, 2025, after the close

10-Q filed Nov 10, 2025, 41 days after period end · 0001193125-25-274277

Q3 2025 · 10-Q
Revenue$10.79M+57.6% vs Q3 2024+12.1% vs Q2 2025
Net Income-$9.20MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.72N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$10,883,000N/M
Operating Cash Flowderived-$15,133,000N/M
Free Cash Flowderived-$15,175,000N/M
Margins · derived
Operating margin-100.9%+59.2 pt vs Q3 2024
Net margin-85.2%+55.2 pt vs Q3 2024

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Revenue$10.79M$6.85M$0.00—
Net Income-$9.20M-$9.61M-$14.42M-$23.15M
EPS Diluted-$0.72-$1.51-$3.29-$0.48

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR